instruction stringlengths 101 387 | output stringlengths 203 410 |
|---|---|
SUBJECT: Stability concern: Neurovexa excessive sweating
BODY:
During dispensing review, a patient on Neurovexa 100mg for five days reported excessive sweating. No documented drug interactions. Formulation batch checked. Recommend pharmacovigilance notification.
Dr. Karen Thomas | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes excessive sweating in a patient using Neurovexa which qualifies as an Adverse Event."} |
SUBJECT: Case: adverse event on Neurovexa
BODY:
Patient on Neurovexa 400mg for a year. Developed skin discoloration. No prior history. Causality plausible. Please document and follow pharmacovigilance protocol.
Dr. Linda Wilson | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes skin discoloration in a patient using Neurovexa which qualifies as an Adverse Event."} |
SUBJECT: Official query: Duofalene safety concern
BODY:
Official adverse event notification from our hospital network: Duofalene 200mg, five days usage, patient developed nausea. We require formal documentation for our quality assurance process.
Dr. Michelle Moore | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "92%"}, "Analysis": "The email describes nausea in a patient using Duofalene which qualifies as an Adverse Event."} |
SUBJECT: Request for Aztreovent safety concern details
BODY:
Official adverse event notification from our hospital network: Aztreovent 50mg, a month usage, patient developed runny nose. We require formal documentation for our quality assurance process.
Dr. William Garcia | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "97%"}, "Analysis": "The email describes runny nose in a patient using Aztreovent which qualifies as an Adverse Event."} |
SUBJECT: Pharmacy query: Quadrivex adverse event
BODY:
Pharmacy adverse event: Quadrivex 1000mg, eight weeks treatment course, patient reports dark urine. Stability and storage verified. Drug-related cause suspected.
Dr. Linda Scott | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes dark urine in a patient using Quadrivex which qualifies as an Adverse Event."} |
SUBJECT: Axicilta safety concern - commercial inquiry
BODY:
Official adverse event notification from our hospital network: Axicilta 25mg, three weeks usage, patient developed muscle pain. We require formal documentation for our quality assurance process.
Dr. Linda Anderson | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes muscle pain in a patient using Axicilta which qualifies as an Adverse Event."} |
SUBJECT: Internal escalation: Seldavira adverse event
BODY:
Escalating to senior management: A patient on Seldavira 600mg for five days presented with palpitations. Medical affairs and pharmacovigilance must coordinate a response.
Dr. Karen Jones | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes palpitations in a patient using Seldavira which qualifies as an Adverse Event."} |
SUBJECT: Urgent: Brexucel patient report status
BODY:
FYI urgent: Brexucel 10mg user, ten days in, reporting skin discoloration. Can someone from medical jump on this before the client escalates?
Dr. Matthew Brown | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes skin discoloration in a patient using Brexucel which qualifies as an Adverse Event."} |
SUBJECT: Aztreovent adverse event - commercial inquiry
BODY:
Official adverse event notification from our hospital network: Aztreovent 150mg, a week usage, patient developed eye pain. We require formal documentation for our quality assurance process.
Dr. Jessica Young | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "98%"}, "Analysis": "The email describes eye pain in a patient using Aztreovent which qualifies as an Adverse Event."} |
SUBJECT: Quick question: Emtridex patient report
BODY:
Field issue: Emtridex 500mg, a week therapy, patient has cough. Need talking points ASAP for my next call.
Dr. Michelle Sanchez | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes cough in a patient using Emtridex which qualifies as an Adverse Event."} |
SUBJECT: Stability concern: Onemanol patient report
BODY:
Adverse reaction documentation: Patient administered Onemanol 25mg over two months presenting with bruising. No administration errors identified.
Dr. Richard Ramirez | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "94%"}, "Analysis": "The email describes bruising in a patient using Onemanol which qualifies as an Adverse Event."} |
SUBJECT: Mediaxab: adverse event observed
BODY:
Adverse event to report: Mediaxab 50mg, three weeks on therapy, patient now has slurred speech. No confounding meds noted.
Dr. Joshua Moore | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes slurred speech in a patient using Mediaxab which qualifies as an Adverse Event."} |
SUBJECT: Bictenox adverse event - need fast answer
BODY:
Field issue: Bictenox 2g, four weeks therapy, patient has joint pain. Need talking points ASAP for my next call.
Dr. Susan Allen | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes joint pain in a patient using Bictenox which qualifies as an Adverse Event."} |
SUBJECT: Bictenox causing safety concern - scared
BODY:
I have been taking Bictenox 300mg for two days and now I have terrible memory loss. I am really scared and do not know what to do. This is affecting my life badly. Please help me urgently.
Dr. James Hill | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes memory loss in a patient using Bictenox which qualifies as an Adverse Event."} |
SUBJECT: Brexucel - adverse event
BODY:
Patient on Brexucel 300mg for four weeks. Developed fever. No prior history. Causality plausible. Please document and follow pharmacovigilance protocol.
Dr. Kenneth Garcia | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "97%"}, "Analysis": "The email describes fever in a patient using Brexucel which qualifies as an Adverse Event."} |
SUBJECT: Need urgent advice: Sacituvax safety concern
BODY:
Ever since I started Sacituvax 250mg eight weeks ago, I have been suffering from bad taste in mouth. I cannot sleep, I cannot work, and I feel helpless. Is this normal?
Dr. Emily Hill | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes bad taste in mouth in a patient using Sacituvax which qualifies as an Adverse Event."} |
SUBJECT: Inspection follow-up: Bictenox injection site pain
BODY:
Regulatory filing question: For Bictenox 500mg, has injection site pain after three days of therapy been documented in periodic safety update reports?
Dr. Steven Davis | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "98%"}, "Analysis": "The email describes injection site pain in a patient using Bictenox which qualifies as an Adverse Event."} |
SUBJECT: Request for Brexucel safety concern details
BODY:
As part of our institutional formulary review, we are documenting that a patient exposed to Brexucel 500mg for three days experienced swelling. Please supply related safety data for committee review.
Dr. James Jones | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "98%"}, "Analysis": "The email describes swelling in a patient using Brexucel which qualifies as an Adverse Event."} |
SUBJECT: Business correspondence: Sacituvax adverse event
BODY:
Official adverse event notification from our hospital network: Sacituvax 800mg, a year usage, patient developed vomiting. We require formal documentation for our quality assurance process.
Dr. Kimberly Wilson | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes vomiting in a patient using Sacituvax which qualifies as an Adverse Event."} |
SUBJECT: Request for Mediaxab wheezing details
BODY:
Official adverse event notification from our hospital network: Mediaxab 75mg, two months usage, patient developed wheezing. We require formal documentation for our quality assurance process.
Dr. William Ramirez | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes wheezing in a patient using Mediaxab which qualifies as an Adverse Event."} |
SUBJECT: Aztreovent adverse event - demands resolution
BODY:
This is unacceptable. Aztreovent 250mg prescribed for six months has led to tingling. We need answers now and a full incident report.
Dr. William Thomas | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "92%"}, "Analysis": "The email describes tingling in a patient using Aztreovent which qualifies as an Adverse Event."} |
SUBJECT: Quick question: Duofalene frequent urination
BODY:
Quick heads up: a client on Duofalene 600mg for three days just called about frequent urination. Need a fast medical response to protect the account.
Dr. Sarah Jones | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes frequent urination in a patient using Duofalene which qualifies as an Adverse Event."} |
SUBJECT: Need urgent advice: Emtridex adverse event
BODY:
I have been taking Emtridex 25mg for eight weeks and now I have terrible loss of appetite. I am really scared and do not know what to do. This is affecting my life badly. Please help me urgently.
Dr. Kimberly Walker | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes loss of appetite in a patient using Emtridex which qualifies as an Adverse Event."} |
SUBJECT: Immediate attention: Sacituvax adverse event
BODY:
This is unacceptable. Sacituvax 600mg prescribed for four days has led to bad taste in mouth. We need answers now and a full incident report.
Dr. Ashley Jackson | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "94%"}, "Analysis": "The email describes bad taste in mouth in a patient using Sacituvax which qualifies as an Adverse Event."} |
SUBJECT: Cardeviro patient report - procurement review
BODY:
As part of our institutional formulary review, we are documenting that a patient exposed to Cardeviro 0.5mg for two days experienced swelling. Please supply related safety data for committee review.
Dr. Michelle Wright | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "98%"}, "Analysis": "The email describes swelling in a patient using Cardeviro which qualifies as an Adverse Event."} |
SUBJECT: Need urgent advice: Cardeviro adverse event
BODY:
I have been taking Cardeviro 20mg for a year and now I have terrible numbness. I am really scared and do not know what to do. This is affecting my life badly. Please help me urgently.
Dr. Andrew Garcia | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes numbness in a patient using Cardeviro which qualifies as an Adverse Event."} |
SUBJECT: Cardeviro safety concern - commercial inquiry
BODY:
Official adverse event notification from our hospital network: Cardeviro 800mg, a year usage, patient developed hearing loss. We require formal documentation for our quality assurance process.
Dr. Dorothy Garcia | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes hearing loss in a patient using Cardeviro which qualifies as an Adverse Event."} |
SUBJECT: Business correspondence: Sacituvax blood in stool
BODY:
As part of our institutional formulary review, we are documenting that a patient exposed to Sacituvax 150mg for a month experienced blood in stool. Please supply related safety data for committee review.
Dr. Margaret Rodriguez | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "99%"}, "Analysis": "The email describes blood in stool in a patient using Sacituvax which qualifies as an Adverse Event."} |
SUBJECT: Formulation review: Oncirexal suicidal thoughts
BODY:
Pharmacy adverse event: Oncirexal 1g, a week treatment course, patient reports suicidal thoughts. Stability and storage verified. Drug-related cause suspected.
Dr. Joshua Wilson | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes suicidal thoughts in a patient using Oncirexal which qualifies as an Adverse Event."} |
SUBJECT: Promethazine blood in stool - follow up
BODY:
Field issue: Promethazine 1000mg, ten days therapy, patient has blood in stool. Need talking points ASAP for my next call.
Dr. Steven Wright | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "94%"}, "Analysis": "The email describes blood in stool in a patient using Promethazine which qualifies as an Adverse Event."} |
SUBJECT: Stability concern: Onemanol safety concern
BODY:
Pharmacy adverse event: Onemanol 600mg, a week treatment course, patient reports joint pain. Stability and storage verified. Drug-related cause suspected.
Dr. Charles Davis | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes joint pain in a patient using Onemanol which qualifies as an Adverse Event."} |
SUBJECT: Internal escalation: Seldavira agitation
BODY:
Escalating to senior management: A patient on Seldavira 1g for eight weeks presented with agitation. Medical affairs and pharmacovigilance must coordinate a response.
Dr. Charles Allen | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "94%"}, "Analysis": "The email describes agitation in a patient using Seldavira which qualifies as an Adverse Event."} |
SUBJECT: Case: patient report on Neurovexa
BODY:
Adverse event to report: Neurovexa 200mg, five days on therapy, patient now has allergic reaction. No confounding meds noted.
Dr. Lisa Rodriguez | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes allergic reaction in a patient using Neurovexa which qualifies as an Adverse Event."} |
SUBJECT: Technical assessment: Oncirexal adverse event
BODY:
Adverse reaction documentation: Patient administered Oncirexal 1mg over a year presenting with itching. No administration errors identified.
Dr. Elizabeth Wright | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "92%"}, "Analysis": "The email describes itching in a patient using Oncirexal which qualifies as an Adverse Event."} |
SUBJECT: Clinical note: wheezing with Axicilta
BODY:
wheezing reported in patient using Axicilta 250mg. Duration of therapy: four days. Consider updating safety profile.
Dr. Betty Williams | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "98%"}, "Analysis": "The email describes wheezing in a patient using Axicilta which qualifies as an Adverse Event."} |
SUBJECT: Onemanol safety concern - demands resolution
BODY:
Critical adverse event: Onemanol 75mg, two days exposure, resulted in chest pain. This must be escalated to your safety team immediately.
Dr. Sarah Hernandez | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes chest pain in a patient using Onemanol which qualifies as an Adverse Event."} |
SUBJECT: Urgent: Promethazine patient report status
BODY:
Quick heads up: a client on Promethazine 300mg for two weeks just called about itching. Need a fast medical response to protect the account.
Dr. William Harris | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "94%"}, "Analysis": "The email describes itching in a patient using Promethazine which qualifies as an Adverse Event."} |
SUBJECT: Official query: Brexucel safety concern
BODY:
As part of our institutional formulary review, we are documenting that a patient exposed to Brexucel 0.5mg for three weeks experienced photosensitivity. Please supply related safety data for committee review.
Dr. Maria Gonzalez | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "98%"}, "Analysis": "The email describes photosensitivity in a patient using Brexucel which qualifies as an Adverse Event."} |
SUBJECT: URGENT: Aztreovent allergic reaction
BODY:
We are extremely concerned. After a year on Aztreovent 200mg, a patient reported allergic reaction. We expect immediate acknowledgment and investigation.
Dr. Maria Davis | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "99%"}, "Analysis": "The email describes allergic reaction in a patient using Aztreovent which qualifies as an Adverse Event."} |
SUBJECT: URGENT: Trifovir safety concern
BODY:
Critical adverse event: Trifovir 25mg, eight weeks exposure, resulted in diarrhea. This must be escalated to your safety team immediately.
Dr. Matthew Ramirez | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes diarrhea in a patient using Trifovir which qualifies as an Adverse Event."} |
SUBJECT: safety concern: Bictenox
BODY:
Case summary: Bictenox 75mg, three days exposure, new onset cough. Requires adverse event filing.
Dr. Joshua Gonzalez | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "94%"}, "Analysis": "The email describes cough in a patient using Bictenox which qualifies as an Adverse Event."} |
SUBJECT: Re: Emtridex patient report - action needed
BODY:
Quick heads up: a client on Emtridex 600mg for a week just called about dark urine. Need a fast medical response to protect the account.
Dr. Matthew Sanchez | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "92%"}, "Analysis": "The email describes dark urine in a patient using Emtridex which qualifies as an Adverse Event."} |
SUBJECT: Re: Quadrivex safety concern - action needed
BODY:
FYI urgent: Quadrivex 2g user, two weeks in, reporting blood in stool. Can someone from medical jump on this before the client escalates?
Dr. Donna Smith | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "97%"}, "Analysis": "The email describes blood in stool in a patient using Quadrivex which qualifies as an Adverse Event."} |
SUBJECT: Regulatory query: Seldavira safety concern
BODY:
During inspection preparation, we identified a case of palpitations associated with Seldavira 20mg after three weeks. Is this included in the current benefit-risk evaluation?
Dr. Andrew Walker | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes palpitations in a patient using Seldavira which qualifies as an Adverse Event."} |
SUBJECT: Re: Brexucel rash - action needed
BODY:
FYI urgent: Brexucel 10mg user, two weeks in, reporting rash. Can someone from medical jump on this before the client escalates?
Dr. Joseph Martinez | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes rash in a patient using Brexucel which qualifies as an Adverse Event."} |
SUBJECT: Business correspondence: Quadrivex injection site pain
BODY:
As part of our institutional formulary review, we are documenting that a patient exposed to Quadrivex 100mg for four days experienced injection site pain. Please supply related safety data for committee review.
Dr. Kimberly Sanchez | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes injection site pain in a patient using Quadrivex which qualifies as an Adverse Event."} |
SUBJECT: Distressed by Bictenox patient report
BODY:
Ever since I started Bictenox 50mg three months ago, I have been suffering from injection site pain. I cannot sleep, I cannot work, and I feel helpless. Is this normal?
Dr. Ashley Brown | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "98%"}, "Analysis": "The email describes injection site pain in a patient using Bictenox which qualifies as an Adverse Event."} |
SUBJECT: Internal escalation: Duofalene patient report
BODY:
Escalating to senior management: A patient on Duofalene 600mg for three months presented with bad taste in mouth. Medical affairs and pharmacovigilance must coordinate a response.
Dr. Dorothy Allen | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "94%"}, "Analysis": "The email describes bad taste in mouth in a patient using Duofalene which qualifies as an Adverse Event."} |
SUBJECT: Sacituvax safety concern - commercial inquiry
BODY:
As part of our institutional formulary review, we are documenting that a patient exposed to Sacituvax 1g for three months experienced hair loss. Please supply related safety data for committee review.
Dr. Emily Young | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "94%"}, "Analysis": "The email describes hair loss in a patient using Sacituvax which qualifies as an Adverse Event."} |
SUBJECT: Action required: Aztreovent adverse event
BODY:
This issue has been flagged internally. Aztreovent 100mg, two weeks duration, resulting in blurred vision. Cross-functional team review required by end of week.
Dr. Joshua Garcia | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes blurred vision in a patient using Aztreovent which qualifies as an Adverse Event."} |
SUBJECT: Emtridex patient report - demands resolution
BODY:
Critical adverse event: Emtridex 75mg, two days exposure, resulted in erectile dysfunction. This must be escalated to your safety team immediately.
Dr. Lisa Wright | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "99%"}, "Analysis": "The email describes erectile dysfunction in a patient using Emtridex which qualifies as an Adverse Event."} |
SUBJECT: Case: patient report on Quadrivex
BODY:
Adverse event to report: Quadrivex 2g, ten days on therapy, patient now has wheezing. No confounding meds noted.
Dr. Paul Smith | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "98%"}, "Analysis": "The email describes wheezing in a patient using Quadrivex which qualifies as an Adverse Event."} |
SUBJECT: Business correspondence: Viroblock safety concern
BODY:
Official adverse event notification from our hospital network: Viroblock 300mg, two days usage, patient developed excessive thirst. We require formal documentation for our quality assurance process.
Dr. Thomas Moore | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "92%"}, "Analysis": "The email describes excessive thirst in a patient using Viroblock which qualifies as an Adverse Event."} |
SUBJECT: Regulatory query: Onemanol rash
BODY:
During inspection preparation, we identified a case of rash associated with Onemanol 25mg after a year. Is this included in the current benefit-risk evaluation?
Dr. Dorothy Wright | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes rash in a patient using Onemanol which qualifies as an Adverse Event."} |
SUBJECT: Duofalene causing patient report - scared
BODY:
Ever since I started Duofalene 25mg a month ago, I have been suffering from allergic reaction. I cannot sleep, I cannot work, and I feel helpless. Is this normal?
Dr. Susan Brown | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes allergic reaction in a patient using Duofalene which qualifies as an Adverse Event."} |
SUBJECT: Immediate attention: Sacituvax safety concern
BODY:
This requires immediate attention. A patient on Sacituvax 300mg for two days developed severe fever. We demand an urgent safety review and a response within 24 hours.
Dr. Donald Taylor | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes fever in a patient using Sacituvax which qualifies as an Adverse Event."} |
SUBJECT: Neurovexa: adverse event observed
BODY:
headache reported in patient using Neurovexa 1000mg. Duration of therapy: a week. Consider updating safety profile.
Dr. Sarah Gonzalez | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes headache in a patient using Neurovexa which qualifies as an Adverse Event."} |
SUBJECT: Official query: Duofalene adverse event
BODY:
As part of our institutional formulary review, we are documenting that a patient exposed to Duofalene 1000mg for a year experienced palpitations. Please supply related safety data for committee review.
Dr. Charles White | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes palpitations in a patient using Duofalene which qualifies as an Adverse Event."} |
SUBJECT: Clinical note: eye pain with Axicilta
BODY:
eye pain reported in patient using Axicilta 250mg. Duration of therapy: three days. Consider updating safety profile.
Dr. Kenneth Harris | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "99%"}, "Analysis": "The email describes eye pain in a patient using Axicilta which qualifies as an Adverse Event."} |
SUBJECT: Pharmacy query: Cardeviro safety concern
BODY:
Adverse reaction documentation: Patient administered Cardeviro 1mg over three days presenting with bad taste in mouth. No administration errors identified.
Dr. Anthony Wright | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes bad taste in mouth in a patient using Cardeviro which qualifies as an Adverse Event."} |
SUBJECT: Inspection follow-up: Mediaxab safety concern
BODY:
In the context of our ongoing regulatory review, please confirm whether vaginal irritation has been reported with Mediaxab 100mg during clinical trials or post-market surveillance following two months of use.
Dr. Sandra White | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "98%"}, "Analysis": "The email describes vaginal irritation in a patient using Mediaxab which qualifies as an Adverse Event."} |
SUBJECT: Duofalene hypoglycemia - regulatory assessment
BODY:
In the context of our ongoing regulatory review, please confirm whether hypoglycemia has been reported with Duofalene 0.5mg during clinical trials or post-market surveillance following four weeks of use.
Dr. Sandra Nguyen | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "97%"}, "Analysis": "The email describes hypoglycemia in a patient using Duofalene which qualifies as an Adverse Event."} |
SUBJECT: Business correspondence: Duofalene adverse event
BODY:
Official adverse event notification from our hospital network: Duofalene 5mg, three months usage, patient developed slurred speech. We require formal documentation for our quality assurance process.
Dr. Kenneth Harris | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes slurred speech in a patient using Duofalene which qualifies as an Adverse Event."} |
SUBJECT: Escalation: Sacituvax adverse event
BODY:
Leadership notification: Patient safety event involving Sacituvax 600mg after two days with hyperglycemia. Legal and medical teams should be briefed.
Dr. Lisa Moore | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes hyperglycemia in a patient using Sacituvax which qualifies as an Adverse Event."} |
SUBJECT: Serious Viroblock menstrual irregularities issue
BODY:
This requires immediate attention. A patient on Viroblock 300mg for three months developed severe menstrual irregularities. We demand an urgent safety review and a response within 24 hours.
Dr. Donna Thomas | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes menstrual irregularities in a patient using Viroblock which qualifies as an Adverse Event."} |
SUBJECT: Critical: Brexucel patient report
BODY:
We are extremely concerned. After six months on Brexucel 300mg, a patient reported sore throat. We expect immediate acknowledgment and investigation.
Dr. Nancy Nguyen | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes sore throat in a patient using Brexucel which qualifies as an Adverse Event."} |
SUBJECT: Duofalene adverse event - management review
BODY:
Leadership notification: Patient safety event involving Duofalene 500mg after three days with injection site redness. Legal and medical teams should be briefed.
Dr. Karen Martin | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes injection site redness in a patient using Duofalene which qualifies as an Adverse Event."} |
SUBJECT: Worried about Seldavira hyperglycemia
BODY:
My doctor put me on Seldavira 800mg. After ten days I started getting hyperglycemia. It is getting worse every day and I am afraid something is seriously wrong. Please respond.
Dr. Jessica Walker | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "94%"}, "Analysis": "The email describes hyperglycemia in a patient using Seldavira which qualifies as an Adverse Event."} |
SUBJECT: Request for Trifovir dizziness details
BODY:
Official adverse event notification from our hospital network: Trifovir 600mg, a week usage, patient developed dizziness. We require formal documentation for our quality assurance process.
Dr. Susan Martin | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "98%"}, "Analysis": "The email describes dizziness in a patient using Trifovir which qualifies as an Adverse Event."} |
SUBJECT: Re: Onemanol patient report - action needed
BODY:
FYI urgent: Onemanol 800mg user, three weeks in, reporting dizziness. Can someone from medical jump on this before the client escalates?
Dr. Kimberly Miller | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes dizziness in a patient using Onemanol which qualifies as an Adverse Event."} |
SUBJECT: Distressed by Cardeviro diarrhea
BODY:
I am writing because I am very worried. Cardeviro 20mg taken for two months has caused diarrhea. I never had this before and I need to know if I should stop.
Dr. Charles Walker | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes diarrhea in a patient using Cardeviro which qualifies as an Adverse Event."} |
SUBJECT: Distressed by Onemanol adverse event
BODY:
I am writing because I am very worried. Onemanol 500mg taken for three days has caused fever. I never had this before and I need to know if I should stop.
Dr. Kenneth Martin | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes fever in a patient using Onemanol which qualifies as an Adverse Event."} |
SUBJECT: Inspection follow-up: Duofalene bad taste in mouth
BODY:
During inspection preparation, we identified a case of bad taste in mouth associated with Duofalene 2g after a year. Is this included in the current benefit-risk evaluation?
Dr. Nancy Nguyen | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes bad taste in mouth in a patient using Duofalene which qualifies as an Adverse Event."} |
SUBJECT: Request for Seldavira adverse event details
BODY:
As part of our institutional formulary review, we are documenting that a patient exposed to Seldavira 500mg for a week experienced anxiety. Please supply related safety data for committee review.
Dr. Charles Garcia | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes anxiety in a patient using Seldavira which qualifies as an Adverse Event."} |
SUBJECT: Regulatory query: Viroblock patient report
BODY:
Regulatory filing question: For Viroblock 2g, has skin discoloration after five days of therapy been documented in periodic safety update reports?
Dr. Daniel Williams | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes skin discoloration in a patient using Viroblock which qualifies as an Adverse Event."} |
SUBJECT: Quick question: Seldavira adverse event
BODY:
FYI urgent: Seldavira 100mg user, eight weeks in, reporting excessive sweating. Can someone from medical jump on this before the client escalates?
Dr. Sandra Davis | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes excessive sweating in a patient using Seldavira which qualifies as an Adverse Event."} |
SUBJECT: Need urgent advice: Axicilta safety concern
BODY:
I am writing because I am very worried. Axicilta 150mg taken for three days has caused jaundice. I never had this before and I need to know if I should stop.
Dr. Kevin Torres | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "94%"}, "Analysis": "The email describes jaundice in a patient using Axicilta which qualifies as an Adverse Event."} |
SUBJECT: Regulatory query: Duofalene safety concern
BODY:
Regulatory filing question: For Duofalene 75mg, has fatigue after five days of therapy been documented in periodic safety update reports?
Dr. Linda Hill | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes fatigue in a patient using Duofalene which qualifies as an Adverse Event."} |
SUBJECT: Neurovexa safety concern - commercial inquiry
BODY:
Official adverse event notification from our hospital network: Neurovexa 200mg, three months usage, patient developed fatigue. We require formal documentation for our quality assurance process.
Dr. Karen Torres | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "99%"}, "Analysis": "The email describes fatigue in a patient using Neurovexa which qualifies as an Adverse Event."} |
SUBJECT: Immediate attention: Viroblock difficulty swallowing
BODY:
We are extremely concerned. After a month on Viroblock 75mg, a patient reported difficulty swallowing. We expect immediate acknowledgment and investigation.
Dr. Linda Walker | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes difficulty swallowing in a patient using Viroblock which qualifies as an Adverse Event."} |
SUBJECT: Serious Viroblock safety concern issue
BODY:
We are extremely concerned. After three days on Viroblock 150mg, a patient reported itching. We expect immediate acknowledgment and investigation.
Dr. Daniel Sanchez | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes itching in a patient using Viroblock which qualifies as an Adverse Event."} |
SUBJECT: Critical: Bictenox safety concern
BODY:
Critical adverse event: Bictenox 75mg, two days exposure, resulted in erectile dysfunction. This must be escalated to your safety team immediately.
Dr. James Wright | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "97%"}, "Analysis": "The email describes erectile dysfunction in a patient using Bictenox which qualifies as an Adverse Event."} |
SUBJECT: Regulatory query: Cardeviro patient report
BODY:
During inspection preparation, we identified a case of vomiting associated with Cardeviro 2g after three months. Is this included in the current benefit-risk evaluation?
Dr. Jessica Moore | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes vomiting in a patient using Cardeviro which qualifies as an Adverse Event."} |
SUBJECT: Request for Promethazine adverse event details
BODY:
As part of our institutional formulary review, we are documenting that a patient exposed to Promethazine 600mg for two months experienced dizziness. Please supply related safety data for committee review.
Dr. Nancy Scott | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "97%"}, "Analysis": "The email describes dizziness in a patient using Promethazine which qualifies as an Adverse Event."} |
SUBJECT: Formulation review: Onemanol patient report
BODY:
Pharmacy adverse event: Onemanol 75mg, four weeks treatment course, patient reports hypoglycemia. Stability and storage verified. Drug-related cause suspected.
Dr. Kimberly Jackson | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "97%"}, "Analysis": "The email describes hypoglycemia in a patient using Onemanol which qualifies as an Adverse Event."} |
SUBJECT: Distressed by Quadrivex safety concern
BODY:
I am writing because I am very worried. Quadrivex 20mg taken for three weeks has caused blurred vision. I never had this before and I need to know if I should stop.
Dr. Joseph Hill | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "94%"}, "Analysis": "The email describes blurred vision in a patient using Quadrivex which qualifies as an Adverse Event."} |
SUBJECT: Clinical note: safety concern with Axicilta
BODY:
Adverse event to report: Axicilta 100mg, three months on therapy, patient now has agitation. No confounding meds noted.
Dr. Nancy Nguyen | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "98%"}, "Analysis": "The email describes agitation in a patient using Axicilta which qualifies as an Adverse Event."} |
SUBJECT: URGENT: Duofalene patient report
BODY:
Critical adverse event: Duofalene 800mg, two months exposure, resulted in hair loss. This must be escalated to your safety team immediately.
Dr. Matthew Gonzalez | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes hair loss in a patient using Duofalene which qualifies as an Adverse Event."} |
SUBJECT: Regulatory query: Quadrivex safety concern
BODY:
During inspection preparation, we identified a case of hallucinations associated with Quadrivex 10mg after a week. Is this included in the current benefit-risk evaluation?
Dr. Mark Martinez | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "97%"}, "Analysis": "The email describes hallucinations in a patient using Quadrivex which qualifies as an Adverse Event."} |
SUBJECT: Pharmacy query: Bictenox adverse event
BODY:
Adverse reaction documentation: Patient administered Bictenox 75mg over four weeks presenting with dry mouth. No administration errors identified.
Dr. Ashley Smith | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "97%"}, "Analysis": "The email describes dry mouth in a patient using Bictenox which qualifies as an Adverse Event."} |
SUBJECT: Urgent: Aztreovent patient report status
BODY:
Field issue: Aztreovent 0.5mg, four weeks therapy, patient has fever. Need talking points ASAP for my next call.
Dr. Dorothy Sanchez | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "97%"}, "Analysis": "The email describes fever in a patient using Aztreovent which qualifies as an Adverse Event."} |
SUBJECT: Oncirexal: skin discoloration observed
BODY:
Patient on Oncirexal 20mg for two months. Developed skin discoloration. No prior history. Causality plausible. Please document and follow pharmacovigilance protocol.
Dr. Sarah Jackson | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "92%"}, "Analysis": "The email describes skin discoloration in a patient using Oncirexal which qualifies as an Adverse Event."} |
SUBJECT: Neurovexa patient report - need fast answer
BODY:
FYI urgent: Neurovexa 2g user, a month in, reporting swelling. Can someone from medical jump on this before the client escalates?
Dr. Robert Lee | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes swelling in a patient using Neurovexa which qualifies as an Adverse Event."} |
SUBJECT: Promethazine adverse event - demands resolution
BODY:
This is unacceptable. Promethazine 1000mg prescribed for four weeks has led to fever. We need answers now and a full incident report.
Dr. Richard Lopez | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "99%"}, "Analysis": "The email describes fever in a patient using Promethazine which qualifies as an Adverse Event."} |
SUBJECT: Brexucel causing patient report - scared
BODY:
I have been taking Brexucel 1g for four days and now I have terrible vaginal irritation. I am really scared and do not know what to do. This is affecting my life badly. Please help me urgently.
Dr. Ashley Taylor | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "98%"}, "Analysis": "The email describes vaginal irritation in a patient using Brexucel which qualifies as an Adverse Event."} |
SUBJECT: Oncirexal causing patient report - scared
BODY:
My doctor put me on Oncirexal 75mg. After five days I started getting blood in stool. It is getting worse every day and I am afraid something is seriously wrong. Please respond.
Dr. Steven Thompson | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes blood in stool in a patient using Oncirexal which qualifies as an Adverse Event."} |
SUBJECT: URGENT: Viroblock safety concern
BODY:
We are extremely concerned. After a month on Viroblock 800mg, a patient reported runny nose. We expect immediate acknowledgment and investigation.
Dr. William Thomas | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes runny nose in a patient using Viroblock which qualifies as an Adverse Event."} |
SUBJECT: Neurovexa safety concern - need fast answer
BODY:
Quick heads up: a client on Neurovexa 2g for ten days just called about hallucinations. Need a fast medical response to protect the account.
Dr. Kenneth Brown | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes hallucinations in a patient using Neurovexa which qualifies as an Adverse Event."} |
SUBJECT: Onemanol safety concern - need fast answer
BODY:
Field issue: Onemanol 150mg, two days therapy, patient has fainting. Need talking points ASAP for my next call.
Dr. William Williams | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes fainting in a patient using Onemanol which qualifies as an Adverse Event."} |
SUBJECT: Aztreovent safety concern - follow up
BODY:
Field issue: Aztreovent 100mg, ten days therapy, patient has weakness. Need talking points ASAP for my next call.
Dr. Donald Lopez | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "98%"}, "Analysis": "The email describes weakness in a patient using Aztreovent which qualifies as an Adverse Event."} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.